These examples include imatinib-mediated inhibition of c-KIT in gastrointestinal stromal tumors [30], inhibition of PDGFR-β (platelet-derived growth factor receptor) by imatinib in dermatofibrosarcoma protuberans [31], mTOR inhibition in perivascular epithelioid cell tumors [32] and EZH2 (enhancer of zeste homolog 2) inhibition in INI1-or SMARCA4-deficient sarcomas [33]. This evidence concerns the gene EZH2 and sarcoma.